BusinessCascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal CancerBy Nasdaq OMXSep 27, 2017, 11:00 AM UTC
BusinessCascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceBy Nasdaq OMXSep 20, 2017, 1:01 PM UTC
BusinessClinipace Worldwide Adds Industry Veteran Steve Skolsky to Board of DirectorsBy Nasdaq OMXAug 31, 2017, 1:07 PM UTC
BusinessCascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 CongressBy Nasdaq OMXAug 28, 2017, 12:30 PM UTC
BusinessGlobal Membrane Technology In Pharma, Biopharma And Life Science Market Is Expected To Boost, Driven By Rise In Membrane Technology In Food And Drug IndustriesBy Nasdaq OMXAug 9, 2017, 11:47 AM UTC
BusinessCascadian Therapeutics Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 8, 2017, 8:01 PM UTC
BusinessCascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017By Nasdaq OMXAug 1, 2017, 12:30 PM UTC
BusinessCascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in EuropeBy Nasdaq OMXJul 11, 2017, 12:01 PM UTC
